Updating results

981 results

Sort: Relevance | Date

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: 27 May 2020

Highly specialised technologies guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Highly specialised technologies guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: 13 January 2021

Highly specialised technologies guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: 11 November 2020

Highly specialised technologies guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa in adults and children

Highly specialised technologies guidance Published December 2015

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

Highly specialised technologies guidance Published January 2015

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

Highly specialised technologies guidance Published July 2016

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Highly specialised technologies guidance Published August 2017

Eliglustat for treating type 1 Gaucher disease (HST5)

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Highly specialised technologies guidance Published June 2017

Migalastat for treating Fabry disease (HST4)

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Highly specialised technologies guidance Published February 2017

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Highly specialised technologies guidance Published October 2018

Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Highly specialised technologies guidance Published February 2018

Inotersen for treating hereditary transthyretin amyloidosis (HST9)

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Highly specialised technologies guidance Published May 2019

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Highly specialised technologies guidance Published November 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Highly specialised technologies guidance Published October 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

The V.A.C. Veraflo Therapy system for infected wounds

In development [GID-MT543] Expected publication date: 06 October 2020

Medical technologies guidance In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

SEM Scanner 200 for pressure ulcer prevention

In development [GID-MT533] Expected publication date: 06 July 2020

Medical technologies guidance In development

DHT pilot: Lifelight First for monitoring vital signs

In development [GID-MT532] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: MyCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: Zio XT Service for detecting cardiac arrhythmias

In development [GID-MT534] Expected publication date: TBC

Medical technologies guidance In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 21 December 2020

Medical technologies guidance In development

Leukomed Sorbact

In development [GID-MT541] Expected publication date: 22 December 2020

Medical technologies guidance In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 27 March 2020

Medical technologies guidance In development

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder

In development [GID-MT530] Expected publication date: 01 June 2020

Medical technologies guidance In development

Peezy Midstream for urine collection (SUSPENDED)

In development [GID-MT538] Expected publication date: TBC

Medical technologies guidance In development

DHT pilot: DECODE decision support system for the identification of dementia

In development [GID-MT536] Expected publication date: TBC

Medical technologies guidance In development

Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

The MAGEC system for spinal lengthening in children with scoliosis

In development [GID-MT544] Expected publication date: 15 September 2020

Medical technologies guidance In development

gammaCore for cluster headache (MTG46)

Evidence-based recommendations on gammaCore for cluster headache

Medical technologies guidance Published December 2019

Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy

Medical technologies guidance Published June 2019

Curos for preventing infections when using needleless connectors (MTG44)

Evidence-based recommendations on Curos for preventing infections when using needleless connectors

Medical technologies guidance Published May 2019

Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease (MTG28)

Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in patients with sickle cell disease

Medical technologies guidance Published March 2016

The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)

Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters

Medical technologies guidance Published March 2015 Last updated May 2019

The TURis system for transurethral resection of the prostate (MTG23)

Evidence-based recommendations on the transurethral resection in saline system (TURis) for resection of the prostate

Medical technologies guidance Published February 2015

VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (nerve damage)

Medical technologies guidance Published December 2014 Last updated March 2015

Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

Evidence-based recommendations on the Parafricta Bootees and Undergarments to reduce the development or risk of pressure ulcers caused by skin breakdown

Medical technologies guidance Published November 2014

moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

Evidence-based recommendations on the moorLDI2-BI a laser doppler blood flow imager for burn wound assessment

Medical technologies guidance Published March 2011 Last updated August 2017

The geko device for reducing the risk of venous thromboembolism (MTG19)

Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism (VTE)

Medical technologies guidance Published June 2014

The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

Evidence-based recommendations on the MAGEC system for spinal lengthening in children with scoliosis (curvature of the spine)

Medical technologies guidance Published June 2014

The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)

Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds

Medical technologies guidance Published March 2014 Last updated March 2019

Ambu aScope4 Broncho for use in unexpected difficult airways (MTG14)

Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways

Medical technologies guidance Published July 2013 Last updated June 2019

WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation (AF) when diagnosing and managing hypertension

Medical technologies guidance Published January 2013

EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing

Medical technologies guidance Published January 2013 Last updated October 2019